An Exploratory Clinical Study of HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs HRS 4642 (Primary) ; Nimotuzumab (Primary)
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2025 New trial record